RT Journal Article
SR Electronic
T1 Is Rapid Molecular Testing enough In Screening Resistant Tuberculosis In Community
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.25.21252270
DO 10.1101/2021.02.25.21252270
A1 Dhaker Ashok
A1 Bahal Ashish
A1 Mangal Vishal
A1 K Yadav Arun
A1 Singhal Anuj
A1 Gupta Anoushka
YR 2021
UL http://medrxiv.org/content/early/2021/03/01/2021.02.25.21252270.abstract
AB Background The study aimed to compare the sensitivity and specificity of cartridge based nucleic acid amplification test (CBNAAT) for diagnosis of Drug-Resistant tuberculosis (DRTB) with culture sensitivity assays.Methods Patients with cough symptoms for more than two weeks with any one symptom such as night sweats, fever, and unintentional weight loss were enrolled. Cases where Mycobacterium Tuberculosis was detected on sputum CBNAAT, were included in the study. Demographic variables, clinical features, and chest radiographs were collected. Each sputum sample was divided into three aliquots: smear microscopy, culture, and genotypic drug sensitivity testing (DST). Results of all three diagnostic modalities were compared with CBNAAT.Results Out of 236 patients with sputum positive CBNAAT, 49.4 % (117/236) were rifampicin-resistant while 50. 6 % (119/236) were Rifampicin sensitive. The genotypic DST assays carried out on all enrolled patients showed that 76. 3 % (181/236) patients were resistant to one or more first-line or second-line antitubercular (ATT) drugs, while 23.7 % (55/236) patients were sensitive to all ATT drugs. On concordant analysis of CB NAAT with DST assays, we found that among 119 CB NAAT rifampicin sensitive patients, 66 patients were resistant to first-line or second-line antitubercular drugs.Conclusion This study found that the screening of DRTB with CBNAAT at the community level is suboptimal compared to the gold standard. Although CBNAAT’s sensitivity in detecting DRTB is significantly higher, the specificity is lower in that population who have received ATT earlier.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Ethical Committee at Armed Forces Medical College discussed the project and approved it vide letter number IEC/ Oct/2018 dated 22 Oct 2018All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data is available with the authors on request